Search
- Page Path
- HOME > Search
Review Articles
- Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management
- Joonpyo Lee, Mi-Seung Shin
- Cardiovasc Prev Pharmacother. 2025;7(1):1-8. Published online January 21, 2025
- DOI: https://doi.org/10.36011/cpp.2025.7.e2
- 4,564 View
- 78 Download
-
Abstract
PDF - Nonalcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) are two increasingly prevalent conditions that share common risk factors, including obesity, diabetes, and aging. NAFLD, marked by hepatic steatosis, is a leading cause of liver disease globally, with cardiovascular disease accounting for most deaths among those affected. HFpEF, characterized by diastolic dysfunction and systemic inflammation, accounts for a growing share of heart failure cases, especially among older adults. The bidirectional relationship between NAFLD and HFpEF involves shared mechanisms such as systemic inflammation, insulin resistance, and metabolic dysfunction. These overlapping processes create a vicious cycle that exacerbates each condition. This review emphasizes the shared pathophysiology, risk factors, and management strategies for these interconnected diseases. Promising interventions, including exercise, weight loss, and emerging pharmacological treatments like sodium-glucose cotransporter 2 inhibitors, are effective in addressing both NAFLD and HFpEF. By targeting these common pathways, there is a unique opportunity to develop integrated treatment approaches that could improve outcomes for affected patients.
- The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?
- Dae-Jeong Koo, Won-Young Lee
- Cardiovasc Prev Pharmacother. 2022;4(4):132-141. Published online October 20, 2022
- DOI: https://doi.org/10.36011/cpp.2022.4.e17
- 12,610 View
- 157 Download
- 5 Citations
-
Abstract
PDF
- Nonalcoholic fatty liver disease (NAFLD), which has recently undergone a change in its definition and acronym to “metabolic dysfunction associated fatty liver disease (MAFLD),” is clinically significant as an increasingly prevalent independent risk factor for cardiovascular diseases. Insulin resistance is considered to be a key mechanism in the development and progression of NAFLD/MAFLD, and fatty liver disease itself may exacerbate insulin resistance. In this review, we describe the mechanisms underlying the interaction between insulin resistance and fatty liver, and we summarize the therapeutic attempts based on those mechanisms.
-
Citations
Citations to this article as recorded by
- Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management
Joonpyo Lee, Mi-Seung Shin
Cardiovascular Prevention and Pharmacotherapy.2025; 7(1): 1. CrossRef - Interplay of the pathophysiological mechanisms of non-alcoholic fatty liver disease, diabetes mellitus, and inflammation: A growing threat to public health
Sharon Olabisoye Oladipupo, Emmanuel Henry Ezenabor, Adebola Busola Ojo, Akingbolabo Daniel Ogunlakin, Oluwafemi Adeleke Ojo
Obesity Medicine.2025; 55: 100613. CrossRef - Association of Apolipoprotein C-III Gene Polymorphisms (rs2854116 and rs2854117) with Susceptibility to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Turkish Population
Damla Karaagac, Suat Morkuzu, Naci Senkal, Ersel Bilgin, Yasemin Oyacı, Tufan Tükek, Sacide Pehlivan, Alpay Medetalibeyoglu
Medicina.2025; 61(8): 1479. CrossRef - Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
Inha Jung, Dae-Jeong Koo, Won-Young Lee
Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef - A Comprehensive Review of Pathophysiological Link Between Non-alcoholic Fatty Liver Disease, Insulin Resistance, and Metabolic Syndrome
Eudith Januario, Aly Barakat, Abhivanditha Rajsundar, Zahra Fatima, Varda Nanda Palienkar, Arjun V Bullapur, Sunchandandeep Singh Brar, Punam Kharel, Mishal Mohammed Koyappathodi Machingal, Amena Backosh
Cureus.2024;[Epub] CrossRef
- Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management
First
Prev
